Abstract
Cancer is a heritable disorder of somatic cells: environment and heredity are both important in the carcinogenic process. The primal force is the “two hits” of Knudson’s hypothesis, which has proved true for many tumours, including renal cell carcinoma. Knudson et al. [1, 2] recognised that familial forms of cancer might hold the key to the identification of important regulatory elements known as tumour-suppressor genes. Their observations (i.e., that retinoblastoma tend to be multifocal in familial cases and unifocal in sporadic presentation) led them to propose a two-hit theory of carcinogenesis. Furthermore, Knudson postulated that patients with the familial form of the cancer would be born with one mutant allele and that all cells in that organ or tissue would be at risk, accounting for early onset and the multifocal nature of the disease. In contrast, sporadic tumours would develop only if a mutation occurred in both alleles within the same cell, and, as each event would be expected to occur with low frequency, most tumours would develop late in life and in a unifocal manner [3, 4]. The kidney is affected in a variety of inherited cancer syndromes. For most of them, both the oncogene/tumour-suppressor gene involved and the respective germline mutations have been identified. Each of the inherited syndromes predisposes to distinct types of renal carcinoma. Families with hereditary predisposition to cancer continue to provide a unique opportunity for the identification and characterisation of genes involved in carcinogenesis. A surprising number of genetic syndromes predispose to the development of renal cell carcinoma, and genes associated with five of these syndromes have been already identified: VHL, MET, FH, BHD and HRPT2. Few cancers have as many different types of genetic predisposition as renal cancer, although to date only a small proportion of renal cell cancers can be explained by genetic predisposition.
Similar content being viewed by others
References
Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 69:820–823
Knudson AG, Strong LC (1976) Mutation and cancer: a model for Wilms’ tumor of the kidney. J Natl Cancer Inst 48:313–324
Zimmer M, Iliopoulos O (2003) Molecular genetics of kidney cancer. Cancer Treat Res 116:3–27
Pavlovich CP, Schmidt LS (2004) Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 4:381–393
Al-Awqati Q, Oliver JA (2002) Stem cells in the kidney. Kidney Int 61:387–395
Savage COS (1994) The biology of the glomerulus: endothelial cells. Kidney Int 45:314–319
Johnson RJ, Floege J, Yoshimura A et al (1992) The activated mesangial cell: a glomerular “myofibroblast”. J Am Soc Nephrol 2[Suppl 10]: S190–19
El Nahas AM, Muchaneta-Kubara EC, Essawy M, Soylemezoglu O (1997) Renal fibrosis: insights into pathogenesis and treatment. Int J Biochem Cell Biol 29:55–62
Lidhal P, Hellstrom M, Kalen M et al (1998) Paracrine PDGF-B/PDGF-R beta signalling controls mesangial development in kidney glomeruli. Development 125:3313–3322
Naruse K, Fujieda M, Miyazaki E et al (1999) CD34 expression as a novel marker of transformed mesangial cells in biopsied glomerular diseases. J Pathol 189:105–111
Simmons PJ, Torok-Storb B (1991) CD34 expression by stromal precursors in normal human adult bone marrow. Blood 78:2848–2853
Ng YY, Fan JM, Mu W et al (1999) Glomerular epithelial-myofibroblast transdifferentiation in the evolution of glomerular crescent formation. Nephrol Dial Transpl 14:2860–2872
Jernigan SJ, Eddy AA (2000) Experimental insights into the mechanisms of tubulointerstitial scarring. In: El Nahas AM, Anderson S, Harris KPG (eds) Mechanisms and management of progressive renal failure. Oxford University Press, London, pp 104–145
Fan JM, Ng YY, Hill PA et al (1999) Transforming growth factor-beta regulates tubular epithelial myofibroblast transdifferentiation in vitro. Kidney Int 56:1455–1467
Zeisberg M, Strutz F, Muller GA (2000) Renal fibrosis: an update. Curr Opin Nephrol Hypert 10: 315–320
Lineham WM, Lerman MI, Zbar B (1995) Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. JAMA 273:564–570
Glenn GM, Choyke PL, Zbar B, Lineham WM (1990) Von Hippel-Lindau disease: clinical review and molecular genetics. In: Anderson E (ed.) Problems in urologic surgery: benign and malignant tumors of the kidney. J.B. Lippincott, Philadelphia, pp 312–330
Poston CD, Jaffe GS, Lubensky IA et al (1995) Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetics implications. J Urol 153:22–26
Cohen AJ, Li FP, Berg S et al (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. New Engl J Med 301:592–595
Kovacs G, Brusa P, De Riese W (1989) Tissuespecific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 43:422–427
Zbar B, Tory K, Marine M et al (1994) Hereditary papillary renal cell carcinoma. J Urol 151:561–566
Zbar B, Glenn G, Lubensky I et al (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153:907–912
Weirich G, Glenn G, Junker K et al (1998) Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 160:335–340
Tory K, Brauch H, Linehan M et al (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81: 1097–1101
Shi G, Cannizzaro LA (1996) Mapping of 29 YAC clones and identification of 3 YACs spanning the translocation t(3;8) (p14.2;q24.1) breakpoint at 8q24.1 in hereditary renal cell carcinoma. Cytogenet Cell Genet 75:180–185
Bodmer D, Eleveld MJ, Ligtenberg MJ et al (1998) An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell carcinoma and a t(2;3)(q35;q21) chromosomal translocation. Am J Hum Genet 62:1475–1483
Wang N, Perkins KL (1984) Involvement of band 3p14 in t(3;8) hereditary renal carcinoma. Cancer Genet Cytogenet 11:479–481
Schmidt L, Duh FM, Chen F et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73
Schmidt LS, Warren MB, Nickerson ML et al (2001) Birt Hogg Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69:876–882
Nickerson ML, Warrem MR, Toro JR et al (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with Birt-Hogg-Dubé syndrome. Cancer Cell 2:157–164
Kiuru M, Launonen V, Hietala M et al (2001) Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 159:825–829
Isaacs JT, Jung YJ, Mole DR et al (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143–153
Couch V, Lindor NM, Karnes PS, Michels VV (2000) Von Hippel-Lindau disease. Mayo Clin Proc 75:265–272
Maher ER, Iselius L, Yater JR et al (1991) Von Hippel-Lindau disease: a genetic study. J Med Genet 28:443–447
Lenehan WM, Zbar B, Klausner RD (2001) Renal carcinoma. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Metabolic and molecular basis of inherited disease. McGraw-Hill, New York
Tory K, Braauch H, Linehan WM et al (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81:1097–1101
Latif F, Tory K, Gnarra J et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320
Iliopoulos O, Eng C (2000) Genetics and clinical aspects of familial renal neoplasms. Semin Oncol 27:138–149
Seizinger BR, Rouleau GA, Ozellius LJ et al (1988) Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268–269
Lubensky IA, Gnarra JR, Bertheau P et al (1996) Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disase patients. Am J Pathol 149:2089–2094
Hosoe S, Brauch H, Latif F et al (1990) Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 8:634–640
Richars FM, Maher ER, Latif F et al (1993) Detailed genetic mapping of the von Hippel-Lindau disease tumor suppressor gene. J Med Genet 30: 104–107
Chen F, Kishida T, Yao M et al (1995) Mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75
Abar B, Kishida T, Chen F et al (1996) Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe and Japan. Hum Mutat 8:349–357
Walther MM, Enquist EG, Jennings SB et al (1999) Molecular genetics of renal cell carcinoma. In Vogelzang NJ, Scardino PT, Shipley WU et al (eds) Comprehensive textbook of genitourinary oncology. Williams/Wilkins, Baltimore, pp 116–128
Bottaro DP, Rubin JS, Faletto DL et al (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802–804
Huang Z, Park WS, Pack S et al (1998) Trisomy 7-harboring nonrandom duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 20:66–69
Kovacs G, Ishikawa I (1993) High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 22:135–139
Zambrano NR, Lubensky IA, Merino MJ et al (1999) Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J Urol 162:1246–1258
Kovacs G, Tory K, Kovacs A (1994) Development of papillary renal cell tumours is associated with a loss of Y-chromosome-specific DNA sequences. J Pathol 173:39–44
Thrash-Bingham CA, Salazar H, Freed JJ et al (1995) Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 55:6189–6195
Tonk V, Wilson KS, Timmons CF et al (1995) Renal carcinoma with translocation (X;1): further evidence for cytogenetically defined subtype. Cancer Genet Cytogenet 81:72–75
Kovacs G, Szucs S, Deriese W, Baumgartel H (1978) Specific chromosomal aberration in human renal cell carcinoma. Int J Cancer 40:171–178
Zbar B, Glenn G, Lubensky I et al (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153:907–912
Duh FM, Scherer SW, Tsui LC et al (1997) Gene structure of the human MET proto-oncogene. Oncogene 15:1583–1586
Choyke PL, Glenn GM, Walther MM et al (2003) Hereditary renal cancers. Radiology 226:33–46
Pavlovich CP, Walther MM, Eyler RA et al (2002) Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26:1542–1552
Polascik TJ, Bostwick DG, Cairns P (2002) Molecular genetics and histopathologic features of adult distal nephron tumors. Urology 60:941–946
Birt AR, Hogg GR, Dube WJ (1977) Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113:1674–1677
Pan CC, Chen PC, Chiang H (2004) Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 121:878–883
Petit A, Castillo M, Santos M et al (2004) KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol 28:676–678
Antonelli A, Portesi E, Cozzot A et al (2003) The collecting duct carcinoma of the kidney: a cytogenetical study. Eur Urol 43:680–685
Foster K, Crossey PA, Cairns P et al (1994) Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p,5q,11p,17 and 22. Br J Cancer 69:230–234
Lubinski J, Hadaczek P, Podolski J et al (1994) Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res 54:3710–3713
Knebelmann B, Ananth S, Cohen HT, Sukhatme VP (1998) Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res 58:226–231
Gomella LG, Sargent ER, Wade TP et al (1989) Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res 49:6972–6975
Kinouchi T, Saiki S, Naoe T et al (1989) Correlation of c-myc expression with nuclear pleomorphism in human renal cell carcinoma. Cancer Res 9:3627–3630
Kenck C, Bugert P, Wilhelm M, Kovacs G (1997) Duplication of an approximately 1.5 Mb DNA segment at chromosome 5q22 indicates the locus of a new tumour gene in nonpapillary renal cell carcinomas. Oncogene 14:1093–1098
Kovacs G (1993) Molecular cytogenetics of renal tumors. Adv Cancer Res 62:89–124
Presti JC, Moch H, Reuter VE et al (1996) Renal cell carcinoma genetic analysis by comparative ge nomic hybridation and restriction fragment length polymorphism analysis. J Urol 156:281–285
Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602
Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453–456
Oda H, Nakatsuru Y, Ishikawa T (1995) Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 55:658–662
Hofmockel G, Wittmann A, Dammrich J, Basukas ID (1996) Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res 16:3807–3811
Dijkhuizen T, Van Den Berg E, Van Den Berg A et al (1997) Genetics as a diagnostic tool in sarcomatoid renal cell cancer. Int J Cancer 72:265–269
Teysier JR, Ferre D (1990) Chromosomal changes in renal cell carcinoma. No evidence for correlation with clinical stage. Cancer Genet Cytogenet 45:197–205
Presti JC, Reuter VE, Cordon-Cardo C et al (1993) Allelic deletions in renal tumors: his to patho logical correlations. Cancer Res 53:5780–5783
Wu SQ, Hafez GR, Xing W et al (1996) The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with non-papillary renal cell carcinoma. Cancer 77:1154–1160
Schullerus D, Herbers J, Chudek J et al (1997) Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of nonpapillary renal cell carcinomas. J Pathol 183:151–155
Pisters LL, el-Naggar AK, Luo W et al (1997) C-met proto-oncogen expression in benign and malignant human renal tissues. J Urol 158:724–728
Nakopoulou L, Vouriakou C, Papaliodi E et al (1997) Immunodetection of c-met-oncogene’s protein product in renal cell neoplasia. Path Res Pract 193:299–304
Natali PG, Prat M, Nicotra MR et al (1996) Over-expression of the met-HGF receptor in renal cell carcinomas. Int J Cancer 69:212–217
Sargent ER, Gomella LG, Belldegrun A et al (1989) Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 142:1364–1368
Weidner U, Peter S, Strohmeyer T et al (1990) Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res 50:4504–4509
Bander NH, Cordon-Cardo C, Finstad CL et al (1985) Immunohistologic dissection of the human kidney using monoclonal antibodies. J Urol 133: 502–505
Cohen C, McCue PA, Derose PB (1988). Histogenesis of renal cell carcinoma and oncocytoma. An immunohistochemical study. Cancer 62:1946–1951
Hennigar RA, Spicer SA, Sens DA et al (1986) Histochemical evidence for tubule segmentations in a case of Wilms’ tumor. Am J Clin Pathol 85: 724–731
Medeiros LJ, Michie SA, Johnson DE et al (1988) An immunoperoxidase study of renal cell carcinomas: correlations with nuclear grade, cell type and histologic pattern. Hum Pathol 19:980–987
Wick MR, Cherwitz DL, Manivel JC, Sibley R (1999) Immunohistochemical findings in tumors of the kidney. In Eble JN (ed.) Tumors and tumor-like conditions of the kidneys and ureters. Churchill Livingstone, New York, pp 207–247
Yoshida SO, Iman A, Olson CA, Taylar CR (1986) Proximal renal tubular surface membrane antigens identified in primary and metastatic renal cell carcinomas. Arch Pathol Lab Med 110:825–832
Fleming S, Symes CE (1987) The distribution of cytokeratin antigens in the kidney and in renal tumors. Histopathology 11:157–170
Mc Gregor DK, Khurana KH, Cao C et al (2001) Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody. Renal Cell Carcinoma Marker. Am J Surg Pathol 25: 1485–1492
Pitz S, Moll R, Storkel S, Thoenes W (1987) Expression of intermediate filament proteins in subtypes of renal cell carcinomas and in renal oncocytoma. Distinction of two classes of renal cell tumors. Lab Invest 56:642–653
Chu PG, Weiss LM (2001) Cytokeratin 14 immunoreactivity distinguishes oncocytic tumour from its renal mimics: an immunohistochemical study of 63 cases. Histopathology 39:455–462
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by an unrestricted educational grant from Pfizer.
Rights and permissions
About this article
Cite this article
Valladares Ayerbes, M., Aparicio Gallego, G., Díaz Prado, S. et al. Origin of renal cell carcinomas. Clin Transl Oncol 10, 697–712 (2008). https://doi.org/10.1007/s12094-008-0276-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-008-0276-8